Hilary McElwaine-Johnn

Chief Medical Officer

Hilary joined Karus as Chief Medical Officer (CMO) in 2019. She is a Physician with extensive experience of drug development in venture capital backed biotech companies. She has a track record in delivering small molecules and biologics through multiple phases of development and across varied therapeutic areas including immunotherapeutics and cancer vaccines.

Most recently Hilary was CMO at PsiOxus, a cancer gene therapy company developing immuno-oncology therapeutics for the treatment of solid tumors. Between 2008 and 2015, she was CMO at Vantia Therapeutics, developing small molecule drugs targeting areas of unmet medical need, and prior to this, she was Vice President Clinical at PowderMed, responsible for clinical development of DNA based vaccines for influenza, chronic viral diseases and cancer.

Hilary is a Member of Royal College of Physicians and the Faculty of Pharmaceutical Medicine. She completed her BSc and medical degrees at Imperial College London and St Mary’s Hospital Medical School respectively.